A Review of Recurrent Retinoblastoma: Children’s Hospital Los Angeles Classification and Treatment Guidelines

Berry, Jesse L.; Kogachi, Kaitlin; Murphree, A. Linn; Jubran, Rima; Kim, Jonathan W.

doi:10.1097/iio.0000000000000269

Cited by 24 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initial large dimensions of tumor (Reese-Ellsworth staging groups I to III), and tumor-associated subretinal or vitreous seeds are additional risk factors for tumor recurrence ( Wilson et al, 2007 ). For extraocular relapse specifically, risk factors include tumor remnants in the optic nerve posterior to the lamina cribrosa and microscopic invasions of retinoblastoma into the sclera, choroid, or anterior chamber ( Berry et al, 2019 ). In this case, the large initial tumor in the right eye measuring 9 mm at its base, consistent with Reese-Ellsworth group II, and the presence of vitreous seeding in the left eye predisposed him to tumor recurrence.…”

Section: Discussionmentioning

confidence: 99%

An unusual case of late recurrence of bilateral retinoblastoma

Liu

Ray

2021

Bone Reports

View full text Add to dashboard Cite

Recurrence of retinoblastoma usually occurs within the first few years after treatment. Despite complete tumor regression, delayed relapse of retinoblastoma can occur, predisposing patients to osteosarcoma as second malignancy. Our case was unique regarding the late relapse 13 years after treatment and recurrence at the femur. The initial tumor was treated with chemotherapy, enucleation of the right eye, and plaque radiotherapy. The relapsed tumor was treated with chemotherapy, consolidation, and autologous stem cell transplant. Our patient is currently in complete remission and continues to follow-up with oncology and ophthalmology. This report illustrates the possibility of late recurrence of retinoblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

An unusual case of late recurrence of bilateral retinoblastoma

Liu

Ray

2021

Bone Reports

View full text Add to dashboard Cite

show abstract

“…Recurrence of retinoblastoma may be manifested by a new retinal tumor, vitreous seeding, subretinal seeding, or extraocular findings. [17] Following systemic chemoreduction, the recurrence rate of retinal tumors ranges from 24 to 44%. [18] The majority of new tumors will be detected within three years of initial retinoblastoma diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma

Karimi

Arabi

Shahraki

et al. 2020

JOVR

View full text Add to dashboard Cite

Purpose: To present a case of central serous chorioretinopathy (CSC) in association with regressed familial retinoblastoma. Case Report: A 23-year-old man with regressed unilateral familial retinoblastoma in his left eye presented with decreased vision of the left eye since two months ago. The patient had undergone chemotherapy and cryotherapy for the treatment of retinoblastoma 20 years ago. In the left eye, funduscopy disclosed regressed mass of retinoblastoma, inferonasal to the optic disc, and focal subfoveal neurosensory detachment. Optical coherence tomography (OCT) and fluorescein angiography revealed CSC. As there was no sign of recurrence of retinoblastoma and retinal findings did not show late-onset chemotherapy-related retinopathy, the patient was diagnosed with CSC and followed up. After two months, visual acuity of the left eye improved, and repeated macular OCT revealed absorption of the subretinal fluid. Conclusion: Subretinal fluid accumulation in a patient with regressed retinoblastoma is not always a sign of tumor recurrence or a treatment-related retinopathy.

show abstract

“…On clinical examination, seeding of retinoblastoma tumor cells is a well‐known indicator of advanced disease. In general, the presence of intraocular seeding portends a significantly increased risk of disease recurrence and the need for secondary enucleation 38–41 . Multiple studies have also demonstrated an association between the specific morphology of seeds (as seen on fundus photography) and the overall risk of treatment failure.…”

Section: Monitoring Intraocular Tumor Responsementioning

confidence: 99%

Response criteria for intraocular retinoblastoma: RB‐RECIST

Berry

Munier

Gallie

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression‐free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

show abstract

A Review of Recurrent Retinoblastoma: Children’s Hospital Los Angeles Classification and Treatment Guidelines

Cited by 24 publications

References 42 publications

An unusual case of late recurrence of bilateral retinoblastoma

An unusual case of late recurrence of bilateral retinoblastoma

Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma

Response criteria for intraocular retinoblastoma: RB‐RECIST

Contact Info

Product

Resources

About